Anti-Obesity Drug Market - Strategic Insights and Forecasts (2026-2031)

The anti-obesity drug market, sustaining a 19.04% CAGR, is anticipated to reach USD 116.4 billion in 2031 from USD 40.9 billion in 2025.

Anti-Obesity Drug Market Highlights:

The anti-obesity drug market is anticipated to grow at a steady pace throughout the forecast period. Anti-obesity drugs are used to control weight and provide a way to live a sustainable and healthy life. Anti-obesity drugs are administered to obese individuals, with examples including catecholamine-releasing agents like phentermine and those that act as appetite suppressants. The rising cases of obesity among people, especially adults, and its associated lifelong diseases such as diabetes and cancer, are driving the anti-obesity drug market growth. Moreover, lifestyle changes encouraging obesity coupled with government initiatives and expert research and trials are further expected to propel the anti-obesity drug market size.

Anti-Obesity Drug Market Driver:

• Increasing Prevalence of Obesity

The rising number of obese and overweight people globally pushes the demand for anti-obesity drugs. According to WHO, around 2.8 million people die from obesity or being overweight each year. Moreover, more children are getting obese, raising the concern for anti-obesity medication. For instance, nearly 39 million children under the age of 5 years were obese in 2020, as per the WHO. Obesity and overweight cause more deaths globally compared to underweight. The prevalence of obesity in the US increased from 4.7% in 2017 to 9.4% in 2021, as per the Centers for Disease Control and Prevention. These statistics show the need for anti-obesity medication, thereby highlighting the growth potential of the anti-obesity drug market size. 

• Obesity-Associated Adverse Health Effects

Obesity and overweight cause serious chronic diseases such as type 2 diabetes, certain types of cancer, and premature death. According to CDC, obesity-associated cancer cases exceed 6 million each year in the US. Breast cancer is the most common obesity-associated cancer among women, while colorectal cancer is the most common among men. According to Cancer Research UK, obesity is the second major cause of cancer in the UK, constituting 6% of total cancers, after smoking. Moreover, obesity and overweight are the key causes of type 2 diabetes as they promote inflammation throughout the body. The adverse health effects of obesity, leading to lifelong health problems or death, are expected to aid the growth of the anti-obesity drug market.

• Changing Lifestyle

The lifestyle of people is changing, with more people sticking to laptops all day and following poor diets, causing obesity. There are various lifestyle factors contributing to obesity, such as improper sleep schedules, long sitting times, large portion sizes of food, stress, processed foods, sweetened beverages, emotional eating, and skipping meals. The corporate sector needs its employees to continuously sit for at least 7-8 hours a day for work, which is also a major cause of obesity. More people are equipped with smartphones; for instance, 85% of Americans have smartphones, leading to more obesity. The modern lifestyle of people, causing obesity, is anticipated to boost the anti-obesity market in the coming years.

• Government and Institutional Initiatives

The government of most nations have initiated awareness programs and research developments with international organizations to control obesity and related health problems that are expected to boost the anti-obesity drug market. The World Health Organization provides technical support in the Western Pacific for the execution of a regional framework for protecting children from the harmful impact of food marketing. The Department of Health & Social Care of the UK government launched a Call to Action campaign for overweight people to encourage them to attain a healthier weight and provide them with proper advice to tackle being overweight. These initiatives to raise awareness for weight control are expected to bolster the anti-obesity drug market.

• Opportunities in the Market

Obesity is a major health problem globally, causing 2.8 million deaths each year, as per WHO. To control the obesity problem and reduce the number of death cases, there is a need for anti-obesity drugs, which presents a significant growth opportunity in the anti-obesity drug market. Moreover, government initiatives and research developments, with approvals of weight management drugs in the US, Europe, and other countries, provide further opportunity to develop advanced anti-obesity drugs and provide better weight control solutions.

Anti-Obesity Drug Market Restraints:

Strict government regulations regarding the use of anti-obesity drugs are a restraining factor in the anti-obesity drug market. Moreover, the limited number of people seeking weight management services and adopting obesity control measures is restraining market growth. For instance, only 2% of US adults visit weight management experts to consult on their problems. Additionally, due to potential side effects, anti-obesity drugs are recommended for medication only for adults with a BMI of at least 27 coupled with related comorbidity.

Anti-Obesity Drug Market Geographical Outlook:

• North America is the Dominant Market

The North American region is expected to contribute significantly to the global anti-obesity drug market. The factors affecting the market growth in the region are rising obesity cases coupled with FDA approval of weight management medications. According to SingleCare Administrators, 1 out of 3 US adults are obese with a prevalence rate of at least 20%. Recently, FDA approved the use of six weight loss drugs for long-term use, named Contrave, Saxenda, Xenical, Alli, Wegovy, Imcivree, and Qsymia.  Moreover, the technological advancements and scientific research in the region with the presence of major market players such as Bristol Myers Squibb and Currax Pharmaceuticals drive the adoption of anti-obesity drugs, thereby promoting the anti-obesity drug market growth in the region.

Anti-Obesity Drug Market Players:

• Alizyme, founded in 1995, focuses on medication for obesity and related diseases. It offers appetite-reducing drugs named Zotrim, Trimtone, and PhenQ. Some calorie-burning and weight loss drugs offered by the company are Prime Shred, Instant Knockout, and Phengold.

• Currax Pharmaceuticals LLC, a US-based company, focuses on smoking and obesity medication. The company provides obesity solutions through Contrave®, Ontezra®, Silenor®, and Treximet®.

• GlaxoSmithKline PLC aims to impact the health of 2.5 billion people by 2030. Alli® (orlistat 60mg), developed in 2009, provides weight loss and also received a non-prescription license in Europe.

Anti-Obesity Drug Market Developments:

• February 2026: Eli Lilly and Company introduced a multi-dose KwikPen® delivery system for Zepbound® (tirzepatide), providing patients with a new administration option designed to simplify long-term obesity treatment management.

• December 2025: Eli Lilly and Company announced price reductions for Zepbound® single-dose vials through its LillyDirect platform, aiming to improve affordability and expand patient access to prescription obesity treatment.

• December 2025: Novo Nordisk announced that the U.S. FDA approved the Wegovy® oral pill (semaglutide 25 mg), the first oral GLP-1 therapy for chronic weight management in adults with obesity.

• November 2025: Eli Lilly and Company announced an agreement with the U.S. government to expand access to its obesity medicines, including Zepbound® and the investigational drug orforglipron, for eligible Medicare beneficiaries.

• May 2025: Eli Lilly and Company announced results from the SURMOUNT-5 clinical trial showing its obesity drug Zepbound® (tirzepatide) achieved 20.2% average weight loss, significantly outperforming semaglutide-based therapy in adults with obesity.

Anti-Obesity Drug Market Scope: